Alberta Is Second Canadian Province To Switch To Biosimilars
Follows British Columbia Switching Program That Began This Year
Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.
You may also be interested in...
Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.
Merck, Sharp & Dohme’s Brenzys biosimilar version of Amgen’s Enbrel has received four new indications in Canada, bringing it in line with Sandoz’ rival biosimilar, Erelzi.
Sandoz Canada is continuing to expand its biosimilars footprint with entry into oncology, while also broadening its presence for autoimmune disorders like rheumatoid arthritis.